Avita Medical Inc (RCEL)

R&D to Revenue

23.40%

Quarterly · Period ending:

RCEL logo

RCEL R&D to Revenue

Latest reported23.40%
RCEL Quarterly R&D/Revenue (0.00% → 23.40%)
High-resolution chart · PNG

RCEL r&d to revenue history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Avita Medical Inc R&D to Revenue — Quarterly
Period endingR&D to Revenue
23.3988%
29.24%
32.3002%
21.9669%
27.7826%
33.9419%
26.3501%
27.7704%
32.1619%
46.7759%
47.6576%
32.2023%
43.189%
43.4692%
35.7377%
41.784%
36.7007%
48.017%
60.5248%
48.2621%
38.5675%
46.8796%
65.8632%
66.6798%
47.3304%
64.3539%
70.942%
52.7682%
74.2745%
67.9689%
390.4738%
390.4738%
105.7167%
1,276.88%
832.3244%
832.3198%
569.7414%
569.7382%
482.4718%
482.4712%
444.5139%
444.5105%
270.5149%
270.5143%
569.5067%
569.5058%
192.7968%
192.7963%
120.4146%
120.4148%
41.6381%
41.638%
98.3909%
98.3909%
85.9208%
85.921%
45.3166%
129.6393%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.